BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 37122696)

  • 1. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer.
    Zhu W; Wu J; Huang J; Xiao D; Li F; Wu C; Li X; Zeng H; Zheng J; Lai W; Wen X
    Front Immunol; 2023; 14():1122670. PubMed ID: 37122696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
    Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
    Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
    Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing.
    Zhu W; Huang J; Wu J; Wu C; Ye F; Li X; Lai W
    Heliyon; 2023 Nov; 9(11):e21174. PubMed ID: 37920511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
    Li X; Zheng C; Xue X; Wu J; Li F; Song D; Li X
    Funct Integr Genomics; 2023 Apr; 23(2):115. PubMed ID: 37010617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
    Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
    Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
    Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
    Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
    Liu W; Wang M; Wang M; Liu M
    Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Immune-Related Gene Signature to Identify the Tumor Microenvironment and Prognose Disease Among Patients With Oral Squamous Cell Carcinoma Patients Using ssGSEA: A Bioinformatics and Biological Validation Study.
    Chen Y; Feng Y; Yan F; Zhao Y; Zhao H; Guo Y
    Front Immunol; 2022; 13():922195. PubMed ID: 35935989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic implications for localized prostate cancer by multiomics analyses of the ageing microenvironment landscape.
    Gui C; Wei J; Mo C; Liang Y; Cen J; Chen Y; Wang D; Luo J
    Int J Biol Sci; 2023; 19(12):3951-3969. PubMed ID: 37564213
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
    Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
    BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.
    Su Q; Zhu Y; He B; Dai B; Mu W; Tian J
    Eur J Med Res; 2023 Nov; 28(1):545. PubMed ID: 38017548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
    Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
    Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
    Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
    Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm.
    Yang Z; Zi Q; Xu K; Wang C; Chi Q
    Int Immunopharmacol; 2021 Jan; 90():107238. PubMed ID: 33316739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.